Bolu Abant Izzet Baysal University
Bolu, 14030, Turkey (Türkiye)
NCT Number: NCT03919006
This study aimed to investigate gingival crevicular fluid (GCF), saliva and serum Netrin 1 and Unc5b levels in periodontal health and disease. A total of 60 individuals, 20 patients with periodontitis, 20 with gingivitis and 20 periodontally healthy individuals were included. Whole-mouth and site-specific clinical periodontal parameters including probing depth, clinical attachment level, bleeding on probing, gingival index, plaque index and papillar bleeding index were recorded. GCF, salivary and serum Netrin 1 and Unc5b levels were measured by enzyme-linked immunosorbent assay. Statistical analysis was performed by using non-parametric tests.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Bolu, 14030, Turkey (Türkiye)
A total of 60 individuals, comprising 20 patients with Periodontitis (P Group), 20 patients with gingivitis (G Group), and 20 periodontally healthy controls (H Group) were involved in the study. The patients were diagnosed according to the new classification scheme. Stage and extent of periodontitis were also determined.
The clinical periodontal criteria for the diagnosis of the groups were as follows: the periodontitis group had interdental clinical attachment loss (CAL) ≥5 mm at site of greatest loss and periodontal probing depth (PD) ≥ 6 mm in one or more sites of the 2 non-adjacent teeth in at least two quadrants of the mouth. Accordingly, Stage III generalized periodontitis patients were included in the study. Patients were diagnosed as gingivitis with bleeding on probing ≥ 50 %, PD ≤3 mm, and no radiographic bone loss or CAL. Periodontally healthy individuals had no recorded history of periodontal problems, with PD ≤3 mm, no radiographic bone loss, good oral hygiene, no gingival inflammation.
Inclusion criteria
were as follows: (1) aged >18 years, (2) having at least 16 natural teeth (excluding third molar),(3) nonsmokers with no history of smoking, (4) not having any diagnosed medical illness or drug intake that could affect the periodontal condition. The patients who had (1) taken antibiotics, nonsteroidal antiinflammatory or any other drugs within the past 3 months,(2) received nonsurgical or surgical periodontal treatment, (3) a restorative and endodontic therapy requirement, (4) a removable partial denture and/or having orthodontic therapy were excluded from the study. Current pregnancy or lactation and having serum C reactive protein (CRP) > 3mg/L were also the exclusion criteria.
All individuals were examined at baseline and four weeks after non-surgical periodontal treatment including, whole mouth probing depth (PD), CAL, presence of bleeding on probing (BOP), papillar bleeding index (PBI), gingival index (GI) and plaque index (PI) except the third molars. PD and CAL were measured at six sites per tooth using a manual periodontal probe.
The non-surgical periodontal treatment for periodontitis group included supra- and subgingival scaling, root planing and oral hygiene instructions. Subgingival scaling and root planing were performed under local anesthesia in two sessions within the 48-72 h. Gingivitis group had supra-and subgingival scaling, polishing and oral hygiene instructions. The treatment of gingivitis and periodontitis patients were performed by a periodontist (BM) using hand and ultrasonic instruments. All measurements were performed by the same calibrated examiner (SG).
Saliva sampling
Whole unstimulated saliva samples were collected. Each participant was asked first to rinse the mouth completely with tap water for 1 minutes, wait for 10 minutes, and then expectorate into sterile polypropylene tube for 5 minutes.
Gingival crevicular fluid (GCF) sampling
GCF samples were obtained from two nonadjacent interproximal sites in one single- rooted and one multi-rooted teeth by standardized filter paper strips. GCF was sampled from two sites with GI < 1, PD ≤ 3 mm and without BOP in the healthy group; two sites with GI ≥ 2, PD ≤ 3 mm and positive BOP (visible signs of inflammation) in the gingivitis group; and two deepest pocket (≥ 5 mm) with GI ≥ 2 and positive BOP in periodontitis group.
Serum sampling
Serum samples were taken following saliva and GCF sampling before the periodontal treatment. Six milliliters of venous blood were obtained by a standard venipuncture method and the serum was separated from blood by centrifugation at 1,500 g for 20 minutes.
Measurement of Netrin 1 and Unc5b levels in GCF, Saliva and Serum Samples
Netrin 1 and Unc5b levels in GCF, saliva and serum samples were measured by the enzyme-linked immunosorbent assay (ELISA) using commercial kits according to the manufacturer's guidelines.
Statistical Analysis
All data analyses were performed using a statistical software package. Comparisons of clinical and biochemical parameters between the study groups were performed using the Kruskal- Wallis with Mann Whitney U test with Bonferroni correction method. The intragroup comparisons (at baseline and first month) were performed using Wilcoxon test for paired samples. Associations among levels of the GCF, saliva and serum biomarkers and clinical parameters were also examined using the Spearman rank correlation analysis.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
SRP under local anaesthesia, in a total of 2 clinical visits. Oral hygiene instructions including the modified Bass technique and an appropriate interdental cleaning device with dental floss and interdental brush.
GCF with filter paper using the intracrevicular method, saliva and serum collection
Time frame: Baseline and 4 weeks after treatment
The changes in levels of Netrin-1 and Unc5b 4 weeks after periodontal treatment determined by ELISA.
The changes in levels of Netrin-1 and Unc5b were analyzed to determine as a diagnostic biomarker of periodontal disease.
Time frame: Baseline and 4 weeks after treatment
The changes in probing pocket depth was measured for determining severity of disease and clinical outcome
Time frame: Baseline and 4 weeks after treatment
The changes in probing pocket depth was measured for determining severity of disease
Time frame: Baseline and 4 weeks after treatment
Gingival index was recorded for classifying and evaluating sulcular gingival inflammation. Gingival index was also analyzed to detect the relationship between Netrin-1 and Unc5b.
Time frame: Baseline and 4 weeks after treatment
Plaque index was recorded for determining and classifying oral hygiene status
Time frame: Baseline and 4 weeks after treatment
Bleeding on probing was recorded for classifying and evaluating gingival inflammation especially for apically sulcular inflammation. This was also analyzed to detect the relationship between Netrin-1 and Unc5b.
Time frame: Baseline and 4 weeks after treatment
Papillar bleeding index was recorded for classifying and evaluating the papillar gingival inflammation. This index was also analyzed to detect the relationship between Netrin-1 and Unc5b.
Abant Izzet Baysal University
Other
Levels of Netrin 1 and Its Receptor Unc5b in Gingival Crevicular Fluid, Saliva and Serum in Periodontal Disease and Health
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07691437
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Trabzon, Turkey (Türkiye)
View Trial DetailsNCT07415148
Mouth Diseases, Periodontal Diseases
Malatya, Battalgazi, Turkey (Türkiye)
View Trial DetailsNCT07669233
Gingival Diseases, Gingivitis
Chengdu, Sichuan, China
View Trial DetailsNCT07636993
Mouth Diseases, Periodontal Disease
Al Mansurah, Egypt
View Trial Details